Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dalpiciclib + toremifene
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of dalpiciclib and toremifene, currently being investigated for the treatment of advanced breast cancer. Dalpiciclib (also known as SHR6390) is a small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), developed by Jiangsu Hengrui Pharmaceuticals to block cell cycle progression from the G1 to the S phase. Toremifene is a selective estrogen receptor modulator (SERM) that serves as an endocrine therapy by competing with estrogen for binding sites in target tissues. The combination is being evaluated in a Phase II clinical trial led by the Tianjin Medical University Cancer Institute and Hospital as a first-line treatment for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
- Brand names
- Fareston
- Other names
- dalpiciclib + toremifenSHR6390 + toremifene
02
Targets
CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)ER (Estrogen receptor)
Beyond the preview
Go deeper on dalpiciclib + toremifene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dalpiciclib + toremifene.